课题基金 / 基金详情

项目摘要

项目成果

Andres Finzi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Core B Project Summary: The Goal of the Cellular Core (Core B) is to provide innovation and support to this Program Project to investigate HIV-1 Env antagonism in the context of the conformational states sampled by native HIV-1 Env. Core B will evaluate the impact of the small-molecule antagonists on sensitizing HIV-1-infected cells to antibody-dependent cellular cytotoxicity (ADCC). Core B will also help delineate the mechanisms of action of small-molecule Env inhibitors on trimeric Env expressed at the cell surface. Specifically, Core B will: (a) evaluate the ability of small- molecule Env entry inhibitors for their ability to sensitize HIV-1-infected cells to ADCC and (b) assess their impact on the conformation of functional Env trimers expressed on cell surfaces. Despite not being officially part of the Program Project in the most recent grant period, the Finzi laboratory has been a long-term collaborator and successfully interacted with Virology (Sodroski), Cyclic Peptides and Peptidomimetics (Chaiken), Small Molecule Synthesis (Smith), and Single Molecule FRET (Mothes) Projects to advance the understanding of Env conformational changes at the surface of infected cells, understand how Env conformations are modulated by different small-molecule antagonists generated by the Program Project and assess their impact on Env recognition and ADCC responses mediated by anti-Env antibodies and HIV+ sera.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A new strategy to eliminate HIV-1-infected cells by unlocking the Env trimer
Characterizing HIV-1 Env conformations susceptible to attack by non-neutralizing antibodies
Characterizing HIV-1 Env conformations susceptible to attack by non-neutralizing antibodies
Characterizing HIV-1 Env conformations susceptible to attack by non-neutralizing antibodies
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究